An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting
- 29 September 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in Osteoporosis International
- Vol. 17 (12), 1781-1793
- https://doi.org/10.1007/s00198-006-0193-z
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Cost effectiveness of raloxifene in the treatment of osteoporosis in SwedenPharmacoEconomics, 2004
- A meta-analysis of previous fracture and subsequent fracture riskBone, 2004
- Cost effectiveness of alendronate for the treatment of male osteoporosis in SwedenBone, 2004
- Association Between Vertebral Fracture and Increased Mortality in Osteoporotic PatientsJournal of Bone and Mineral Research, 2003
- Cost Effectiveness of Alendronate (Fosamax??) for the Treatment of Osteoporosis and Prevention of FracturesPharmacoEconomics, 2003
- Health-Related Quality of Life in Postmenopausal Women With Low BMD With or Without Prevalent Vertebral FracturesJournal of Bone and Mineral Research, 2000
- Patients with Prior Fractures Have an Increased Risk of Future Fractures: A Summary of the Literature and Statistical SynthesisJournal of Bone and Mineral Research, 2000
- Accounting for future costs in medical cost-effectiveness analysisJournal of Health Economics, 1997
- The cost of a hip fracture: Estimates for 1,709 patients in SwedenActa Orthopaedica, 1997
- Cost-effectiveness of Fracture Prevention in Established OsteoporosisScandinavian Journal of Rheumatology, 1996